AxoGen, Inc.

AXGN Healthcare Medical Devices

AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.

Revenue
+26.2%
EPS
+178.3%
Free cash flow
+995.0%
Total debt
−73.1%

Quarter to September 2026, against a year earlier

50.00 1.25 +2.56%
Market cap
$2.9B
P/E
0.0×
Fwd P/E
−129×
Dividend yield
—
F-score
5/9
Altman Z
9.23
Beneish M
−2.73
Dividend safety
n/a

AxoGen, Inc. (AXGN) Debt to equity

Alert me on Debt to equity

AxoGen, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.5× from fiscal 2025 (0.5×). Over the past ten years it has ranged from 0.0× (fiscal 2018) to 3.0× (fiscal 2015); the current reading is higher than 36% of that period. That is in line with the Medical Devices industry median of 0.0× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 0.5× (20.59%)
FY2024 0.7× (6.65%)
FY2023 0.7× 6.07%
FY2022 0.7× 11.40%
FY2021 0.6× 37.27%
FY2020 0.4× 1,632.54%
FY2019 0.0× 3,050.00%
FY2018 0.0× (99.92%)
FY2017 1.0× (39.93%)
FY2016 1.6× (45.94%)

Quarterly newest first

Period Debt to equity Change
Sep 2026 0.0× (49.58%)
Jun 2026 0.1× (16.25%)
Mar 2026 0.1× (83.94%)
Dec 2025 0.5× (3.30%)
43 more quarters

Against its own ten years

Low 0.0× High 3.0×
Ten-year median 0.7×
Current reading's percentile 36

Debt to equity against peers

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on AXGN